Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels

Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels

IntroductionDiabetic kidney disease (DKD) has become the leading cause of end-stage renal disease worldwide. Therefore, efforts to understand DKD pathophysiology and prevent its development at the early phase are highly warranted.MethodsHere, we analyzed kidneys from healthy mice, diabetic mice, and...

Full description

Bibliographic Details
Main Authors:	Anxiang Cai, Jianxiao Shen, Xiaoqian Yang, Xinghua Shao, Leyi Gu, Shan Mou, Xiajing Che
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Series:	Frontiers in Immunology
Subjects:	diabetic kidney disease sodium-glucose cotransporter 2 inhibitors inflammation renal tubular cell macrophage
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1205834/full

Similar Items

Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
by: Jing Xu, et al.
Published: (2021-06-01)

Nephroprotective effect of dapagliflozin in type 2 diabetes mellitus: A potential role of Klotho protein
by: I. Topchii, et al.
Published: (2021-06-01)

Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus
by: Yuta Yoshimura, et al.
Published: (2023-10-01)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020-03-01)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020-02-01)

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure
by: Andrew Xanthopoulos, et al.
Published: (2023-08-01)

Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
by: Panshuang Qiao, et al.
Published: (2022-08-01)

An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy
by: Zhenyu Bai, et al.
Published: (2022-09-01)

Glucose Transporters as a Target for Anticancer Therapy
by: Monika Pliszka, et al.
Published: (2021-08-01)

Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study
by: Marcelino Cortés, et al.
Published: (2023-10-01)

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
by: Seul-Gee Lee, et al.
Published: (2022-09-01)

Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
by: Wenqin Guo, et al.
Published: (2024-04-01)

The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following <i>In Vitro</i> Vascular Ischemia/Reperfusion Injury in Rats
by: Sevil Korkmaz-Icöz, et al.
Published: (2021-07-01)

Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study
by: Lauren K. Park, et al.
Published: (2023-05-01)

Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
by: Takeshi Horii, et al.
Published: (2023-11-01)

Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
by: Jaime A Davidson, et al.
Published: (2023-02-01)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
by: Luis Ortega‐Paz, et al.
Published: (2023-02-01)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
by: Genlong Xue, et al.
Published: (2022-10-01)

Safety of dapagliflozin initiation in acute decompensated heart failure patients with reduced left ventricular ejection fraction
by: Anastasiya E. Poskakalova, et al.
Published: (2023-07-01)

Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
by: Xiaolan Ouyang, et al.
Published: (2023-05-01)

Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study
by: Shihan Wang, et al.
Published: (2022-12-01)

Central administration of Dapagliflozin alleviates a hypothalamic neuroinflammatory signature and changing tubular lipid metabolism in type 2 diabetic nephropathy by upregulating MCPIP1
by: Jingjing Da, et al.
Published: (2023-12-01)

Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort
by: Jaehyun Lim, et al.
Published: (2024-02-01)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
by: Hidekatsu Yanai, et al.
Published: (2021-04-01)

Effect of sodium–glucose cotransporter 2 inhibitor medication on new prescriptions of antihypertensives, antigout/antihyperuricemics and antidyslipidemics in Japan: Analysis using the JMDC Claims Database
by: Maki Gouda, et al.
Published: (2022-11-01)

Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor
by: In-Young Nho, et al.
Published: (2018-12-01)

Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease
by: HUANG Lichenlu, ZHANG Jiarui, ZHENG Yongqin, HE Jundong
Published: (2023-10-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
by: Yuto Saijo, et al.
Published: (2023-11-01)

Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2022-12-01)

The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials
by: Feifei Zhou, et al.
Published: (2022-09-01)

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
by: Hiroshi Tobita, MD, PhD, et al.
Published: (2017-01-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia
by: Yu Horiuchi, et al.
Published: (2024-03-01)

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation
by: Nikolaos Karamichalakis, et al.
Published: (2022-07-01)

Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors
by: Serge A. Jabbour, et al.
Published: (2022-10-01)

Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
by: N. B. Perepech, et al.
Published: (2021-07-01)

Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
by: Dominik Kurczyński, et al.
Published: (2022-07-01)

The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?
by: Ayami Naito, et al.
Published: (2024-01-01)